

## R E F E R E N C E S

---

1. Keith MP, Gilliland WR, Updates in the Management of Gout. *The American Journal of Medicine*. 2007;120:221-224.
2. McGill NW, Gout and other crystal-associated arthropathies. *Baillière's Clinical Rheumatology*. 2000;14(3):445-460.
3. Pascual E, Sivera F, Why is gout so poorly managed? *Annals of Rheumatic Disease*. 2007;66:1269-1270.
4. Nuki G, Gout. *Medicine*. 2006;34(10):417-423.
5. Singh J, *et al*. Quality of Care for Gout in the US Needs Improvement. *Arthritis & Rheumatism*. 2007;57(5):822-829.
6. Vázquez-Mellado J, Hernández EA, Burgos-Vargas R., Primary Prevention in Rheumatology: The Importance of Hyperuricemia. *Best Practice & Research Clinical Rheumatology*. 2004;18(2):111-124.
7. Eggebeen A, Gout: An Update. *American Family Physician*. 2007;76(6):801-808.
8. Smelser CD, *et al*. Gout. *eMedicine*. Sept. 25, 2005.
9. Schlesinger N, Management of Acute and Chronic Gouty Arthritis. *Drugs*. 2004;64(21):2399-2416.
10. Altera N, Vaturi M, *et al*. Effect of Weather Conditions on Acute Gouty Arthritis. *Journal of Rheumatology*. 1994;23(1):22-24.
11. Robins, K. *Basic Pathology*. W. B. Saunders Company (1987);98-102.
12. Wortmann, R, Effective management of Gout [Editorial reply]. *The American Journal of Medicine*. 1999;107:406.
13. Chen XL, Schumacher HR, Gout: can we create an evidence-based systematic approach to diagnosis and management? *Best Practice & Research Clinical Rheumatology*. 2006;20(4):673-684.
14. Weaver AL, Case 3: Acute Gout – Risk Factors and Inappropriate Therapy. *American Journal of Medicine*. 2006;119(11A):S9-S12.
15. Yokam T, Rowe L, *Essentials of Skeletal Radiology*. Williams and Wilkins (1987);659-665.
16. Bhandaru R, Acharya R, *et al*. Poster presented at the ACR Meeting 2007: Prevalence of Spinal Gout. Number1602, Poster Board Number 273.
17. Berger JS, *et al*. Gout-Induced Arthropathy in a Knee Following Total Arthroplasty: A Case Report. *Archives of Physical Medicine and Rehabilitation*. 2007;88.

18. Zhang W, Doherty M, Pascual E, *et al.* EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the standing committee for international clinical studies including therapeutics (ESCSIT). *Annals of Rheumatic Disease.* 2006;65:1301–1311.
19. Wortmann RL. Recent advances in the management of gout and hyperuricemia. *Current Opinion in Rheumatology.* 2005;17:319-324.
20. Osterhaus, *et al.* Poster presented at the ACR Meeting 2005. San Diego, CA.
21. Roddy, E., Zhang, W., Doherty, M., Is gout associated with reduced quality of life? A case-control study. *Rheumatology.* 2007;46:1441–1444.
22. Kleinman, *et al.* Poster presented at the ACR Meeting 2005. San Diego, CA.
23. Klippel JH. *Primer on the Rheumatic Diseases*, Edition 12. Atlanta: Arthritis Foundation. 2001. Page 313.
24. Falasca GF. Metabolic diseases: gout. *Clinics in Dermatology.* 2006;24:498-508.
25. Wortmann R. Effective Management of Gout: An Analogy. *The American Journal of Medicine.* 1998;105:513-514.
26. Jordan KM, Cameron JS, *et al.* British Society for Rheumatology and British Health Professionals in Rheumatology Guideline for the Management of Gout. *Rheumatology.* 2007;46:1372-1374.
27. Zhang W, Doherty M, Bardin T, *et al.* EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee For International Clinical Studies Including Therapeutics (ESCSIT). *Annals of Rheumatic Disease.* 2006;65:1312-1324.
28. Schumacher HR, *et al.* Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis. *British Medical Journal.* 2002 324: 1488-1492.
29. Rubin BR. Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout. *Arthritis & Rheumatism.* 2004;50:598-606.
30. Pleuvry BJ. Drugs used to treat muscle and joint disease. *Anesthesia and Intensive Care Medicine.* 2006;7(3):104-106.
31. Weinstein J. Effective treatment of Gout [Letter to the Editor]. *American Journal of Medicine* 1999;107:406.
32. Terkeltaub RA. Gout. *The New England Journal of Medicine.* 2003;349:1647-1655.
33. Wright JD, Pinto AB. Clinical Manifestations and Treatment of Gout. *Primary Care Update for Ob/Gyns.* 2003;10(1):19-23.
34. Alldred A. Gout – pharmacological management. *Hospital Pharmacist.* 2005;12:395-400.
35. Baxter K, *et al.* *Stockley's Drug Interactions.* Eighth Edition. Chicago:Pharmaceutical Press.

36. <http://www.fda.gov/cder/drug/infopage/COX2/NSAIDmedguide.pdf> accessed 2/19/2008.
37. Karalliedde L, Henry AJ. (1998) Handbook of Drug Interactions. New York:Arnold.
38. Niel E, Scherrmann JM. Colchicine today. *Joint Bone Spine*. 2006;73:672-678.
39. Aherin MJ, *et al*. Does colchicine work? *Australia and New Zealand Journal of Medicine*. 1987;17:301-304.
40. Varughese GI, *et al*. A Caveat in the Management of Acute Gout – Letter to the editor. *The American Journal of Medicine*. 2007;120:e31.
41. Hough DW. Gouty Arthritis: The Missed Diagnosis. *Dynamic Chiropractic*. 2000;18(20).
42. Annemans L, Spaepen E, *et al*. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005. *Annals of Rheumatic Disease*. Published online: Nov 2, 2007.
43. Bardin T. Current management of gout in patients unresponsive or allergic to allopurinol. *Joint Bone Spine*. 2004;71:481-485.
44. Shekarriz B, Stoller M. Uric acid nephrolithiasis: current concepts and controversies. *Journal of Urology*. 2002;168:1307-1314.
45. Choi HK, *et al*. Pathogenesis of Gout. *Annals of Internal Medicine*. 2005;143:499-516.
46. Perez-Ruiz F, Martin I, Canteli B. Ultrasonographic measurement of tophi as an outcome measure for chronic gout. *Journal of Rheumatology*. 2007;34(9):1888-93.
47. Perez-Ruiz F, Calabozo M, *et al*. Renal Underexcretion of Uric Acid Is Present in Patients With Apparent High Urinary Uric Acid Output. *Arthritis & Rheumatism*. 2002;47(6):610-613.
48. Feher MD, Hepburn AL, *et al*. Fenofibrate lowers serum urate in patients treated with allopurinol. *Rheumatology*. 2003;42:321-325.
49. Finley, MJ. Case 8: Initiation of Urate-Lowering Therapy for Standard Advanced Gout. *American Journal of Medicine*. 2006;119(11A):S25-S28.
50. Perez-Ruiz, F, *et al*. Effect of Urate-Lowering Therapy on the Velocity of Size Reduction of Tophi in Chronic Gout. *Arthritis & Rheumatism*. 2002;47(4):356-360.
51. Segal JB, Albert D. Diagnosis of Crystal-Induced Arthritis by Synovial Fluid Examination for Crystals: Lessons from an Imperfect Test. *Arthritis Care and Research*. 1999;12(6):376-380.
52. Pascual, *et al*. Best Practice and Research in Clinical Rheumatology. 2004;50:2400-2414.
53. Wallace SL, Robinson H, *et al*. Preliminary criteria for the classification of the acute arthritis of primary gout. *Arthritis & Rheumatology*. 1977;20:896.
54. Coakley G, Mathews C, *et al*. BSR & BHPR, BOA, RCGP and BSAC guidelines for management of the hot swollen joint in adults. *Rheumatology*. 2006;45:1039-1041.

55. Perez-Ruiz F, Naredo E. Imaging modalities and monitoring measures of gout. *Current Opinion in Rheumatology* 2007;19:128-133.
56. Coombs RJ, Pinsky ST, Padanilam TG. Bone scan findings of combined gout and septic arthritis in the same digit. *Clinical Nuclear Medicine*. 2001;26(5):442-443.
57. Haddad RH, Allegra EC. Closer Look At Musculoskeletal Ultrasound. *Arthritis Practitioner*. 2006;2(3):28-32.
58. Thiele RG, Schlesinger N. Diagnosis of gout by ultrasound. *Rheumatology*. 2007;46(7):1116-1121.
59. Wright SA, *et al*. High-resolution ultrasonography of the 1st metatarsal phalangeal joint in gout: A controlled study. *Annals of the Rheumatic Diseases*. 2007;66:859-864.
60. Tavaras JM, Ferrucci JT Jr, editors. *Radiology: Diagnosis, Imaging, Intervention*. Philadelphia, Pa: JB Lippincott Co; 1993.
61. Velilla-Moliner J, *et al*. Podagra, is it always gout? *American Journal of Emergency Medicine*. 2004;22(4):320-321.
62. <http://www.medicinenet.com/hydroxyapatite/article.htm> Accessed: 12/27/07
63. Shmerling RH, Delbanco TL. The rheumatoid factor: an analysis of clinical utility. *American Journal of Medicine*. 1991;91:528-534.
64. Edwards NL. Case 7: Differential Diagnosis of Advanced Gout. *American Journal of Medicine*. 2006;119(11A):S23-S24.
65. Kim KY, *et al*. A literature review of the epidemiology and treatment of acute gout. *Clinical Therapeutics*. 2003;25(6):1617.
66. Choi HK, Atkinson K, Karlson EW, Curhan G. Obesity, weight change, hypertension, diuretic use, and risk of gout in men. *Archives of Internal Medicine*. 2005;165:742-748.
67. Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia: risks and consequences in the Normative Aging Study. *American Journal of Medicine*. 1987;82:421-426.
68. Roubenoff R. Gout and hyperuricemia. *Rheumatic Disease Clinics of North America*. 1990;16:539-550.
69. Chen SY, *et al*. Clinical features of familial gout and effects of probable genetic association between gout and its related disorders. *Metabolism*. 2001;50(10):1203-1207.
70. Bieber JD, Terkeltaub RA, *et al*. Gout: On the Brink of Novel Therapeutic Options for an Ancient Disease. *Arthritis & Rheumatism*. 2004;50(8):2400-2414.
71. Darmawan J, Lutalo SL. Gout and hyperuricaemia. *Baillière's Clinical Rheumatology*. 1995;9(1):83-94.
72. Hasday J, Grum C. Nocturnal Increase of Uricary Uric Acid: Creatinine Ratio. *American Review of Respiratory Disease*. 1987;135:534-538.

73. Bengmark S. Acute and “chronic” phase reaction—a mother of disease. *Clinical Nutrition*. 2004;23:1256-1266.
74. McLachlan A, *et al*. Team-based Approach to Assessing and Managing CVD Risk in Gout Patients Using Acute Predict Electronic Clinical Decision Support. *Heart, Lung and Circulation*. 2007;16:S184.
75. Choi HK, Ford ES, *et al*. Prevalence of the Metabolic Syndrome in Patients With Gout: The Third National Health and Nutrition Examination Survey. *Arthritis & Rheumatism*. 2007;57(1):109-115.
76. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). *Journal of the American Medical Association*. 2001;285:2486-2497.
77. Grundy SM. A Constellation of Complications: The Metabolic Syndrome. *Clinical Cornerstone*. 2005;7(2/3):36-45.
78. Becker MA, Jolly M. Hyperuricemia and Associated Diseases. *Rheumatic Disease Clinics of North America*. 2006;32:275-293.
79. Niskanen KL, Laaksonen ED, *et al*. Uric Acid Level as a Risk Factor for Cardiovascular and All-Cause Mortality in Middle-aged Men: A Prospective Cohort Study. *Archives of Internal Medicine*. 2004;164(14):1546-1551.
80. Takahashi S, Moriwaki Y, *et al*. Increased visceral fat accumulation further aggravates the risk of insulin resistance in Gout. *Metabolism*. 2001;50(4):393-398.
81. Gavin AR, Struthers AD. Hyperuricemia and Adverse Outcomes in Cardiovascular Disease. *American Journal of Cardiovascular Drugs*. 2003;3(5):309-314.
82. Krishnan E, Baker JF. Gout and the Risk of Acute Myocardial Infarction. *Arthritis & Rheumatism*. 2006;54(8):2688-2696.
83. Tomita M, *et al*. Does Hyperuricemia affect mortality? A Prospective Cohort Study of Japanese Male Workers. *Journal of Epidemiology*. 2000;10:403-409.
84. Kang DK, Nakagawa T. Uric acid and chronic renal disease: Possible implication of hyperuricemia on progression of renal disease. *Seminars in Nephrology*. 2005;25(1):43-49.
85. Targ DC, *et al*. Renal function in gout patients. *American Journal of Nephrology*. 1995;15(1):31-7.
86. McCarty CA, *et al*. The Epidemiology of Cataract in Australia. *American Journal of Ophthalmology*. 1999;128(4):446-465.
87. Harrold LR, Yood RA, *et al*. Sex differences in gout epidemiology: evaluation and treatment. *Annals of Rheumatic Disease*. 2006;65:1368-1372.

88. Cleland LG, Hill CL, James MJ. Diet and arthritis. *Baillière's Clinical Rheumatology*. 1995;9(5):771-785.
89. Pi-Sunyer FX. A Review of Long-Term Studies Evaluating the Efficacy of Weight Loss in Ameliorating Disorders Associated with Obesity. *Clinical Therapeutics*. 1996;18(6):1006-1035.
90. Gibson T, Rodgers AV, *et al*. A controlled study of diet in patients with gout. *Annals of Rheumatic Disease*. 1983;42:123-127.
91. Mikuls TR, MacLean CH, *et al*. Quality of care indicators for gout management. *Arthritis & Rheumatism*. 2004;50(3):937-943.
92. Dessein PH, Shipton EA, *et al*. Beneficial effects of weight loss associated with moderate calorie/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout: a pilot study. *Annals of Rheumatic Disease*. 2000;59:539-543.
93. Eastmond CJ, Garton M, Robins S, Riddoch S. The effects of alcoholic beverages on urate metabolism in gout sufferers. *British Journal of Rheumatology*. 1995; 34:756-759.
94. Lee SJ, Terkeltaub RA, Kavanaugh A. Recent Developments in Diet and Gout. *Current Opinion in Rheumatology*. 2006;18(2):193-198.
95. Choi HK, Atkinson K, *et al*. Alcohol intake and risk of incident gout in men: a prospective study. *Lancet*. 2004;363(9417):1277-1281.
96. Choi HK, Curhan G. Alcohol and Gout (Letter to the Editor). *American Journal of Medicine*. 2007;120:e5.
97. Kaneko K, Fujimori S, Akaoka I. Changes caused by ethanol intake on metabolism of hypouricemic agents (combination of allopurinol and benzbromarone). *Advances in Experimental Medicine and Biology* 1991;309A:139-142.
98. Choi HK. Diet, alcohol, and gout: how do we advise patients given recent developments? *Current Rheumatology Reports*. 2005;7:220-226.
99. Wallace KL, Riedel AA, Joseph-Ridge N, Wortmann R. Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. *Journal of Rheumatology*. 2004;31:1582-1587.
100. Parillo M, Rivellese AA, Ciardullo AV, *et al*. A high-monounsaturated-fat/low-carbohydrate diet improves peripheral insulin sensitivity in non-insulin-dependent diabetic patients. *Metabolism*. 1992;41:1373-1378.
101. Griffith RW. Diet and gout - a new approach? *Health and Age*. August 31, 2000.
102. Choi HK, Liu S, Curhan G. Intake of purine-rich foods, protein, and dairy products and relationship to serum levels of uric acid: The Third National Health and Nutrition Examination Survey. *Arthritis & Rheumatism*. 2005;52(1):283-289.
103. Yu KH, See LC, *et al*. Dietary Factors Associated with Hyperuricemia in Adults. *Seminars in Arthritis and Rheumatism*. 2007;37(4):243-250.

104. Adapted from: Peckenpaugh NJ. Nutrition Essentials and Diet Therapy: Tenth Edition. St. Louis: Saunders Elsevier, 2007.
105. Hu FB, Rimm E, Smith-Warner SA, *et al.* Reproducibility and validity of dietary patterns assessed with a food frequency questionnaire. *American Journal of Clinical Nutrition.* 1999;69:243-249.
106. Huang HY, Appel LJ, Choi MJ, *et al.* The effects of vitamin C supplementation on serum concentrations of uric acid. *Arthritis & Rheumatism.* 2005;52:1843-1847.
107. Perez-Ruiz F. New treatments for gout. *Joint Bone Spine.* 2007;74:313-315.
108. Stein HB, Hasan A, Fox IH. Ascorbic Acid-Induced Uricosuria. *Annals of Internal Medicine.* 1976;84:385-388.
109. Matzkies F, Berg G, Madl H. The uricosuric action of protein in man. *Advances in Experimental Medicine and Biology.* 1980;122A:227-231.
110. Lin KC, Lin HY, Chou P. The interaction between uric acid level and other risk factors on the development of gout among asymptomatic hyperuricemia men in a prospective study. *Journal of Rheumatology.* 2000;27:1501-1505.
111. Schlesinger N, Dietary Factors and Hyperuricaemia. *Current Pharmaceutical Design.* 2005;11:4133-4138.
112. Murray M, Pizzorno J. *Encyclopedia of Natural Medicine.* Prima Publishing (1991);332-340.
113. Yamamoto T, Moriwaki Y, *et al.* Effect of sauna bathing and beer ingestion in plasma concentrations of purine bases. *Metabolism.* 2004;53(6):772-776.
114. Zhang YQ, Chaisson CE, *et al.* Poster presented at the ACR Meeting 2006: High Humidity and High Temperature Increase the Risk of Recurrent Gout Attacks: The Online Case-crossover Gout Study. Number 707, Boston, MA.
115. Gallerani M, Govoni M, *et al.* Seasonal variation in the onset of acute microcrystalline arthritis. *Rheumatology.* 1999;36:1003-1006.
116. Griffith RW. Gout, or pseudogout? *Health and Age.* March 12, 2001.
117. Nakagawa T, *et al.* A Causal Role for Uric acid in Fructose-induced Metabolic Syndrome. *American Journal of Physiology - Renal Physiology.* 2006;290:F625-F631.
118. Choi HK, Curhan G. Coffee, Tea, and Caffeine Consumption and Serum Uric Acid Level: The Third National Health and Nutrition Examination Survey. *Arthritis & Rheumatism.* 2007;57(5):816-821.
119. Levinson W, *et al.* To Change or Not To Change: "Sounds Like You Have a Dilemma" *Annals of Internal Medicine.* 2001;135(5):386-391.
120. US Department of Agriculture Food and Nutrition Center. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids (2002/2005).

121. Wantroba AN. Gale Encyclopedia of Alternative Medicine. 2004. Portland:Gale Cengage.
122. Owen PL, Johns T. Xanthine oxidase inhibitory activity of northeastern North American plant remedies used for gout. *Journal of Ethnopharmacology*. 1999;64:149-160.
123. Jacob R, *et al*. Consumption of Cherries Lowers Plasma Urate in Healthy Women. *Journal of Nutrition*. 2003;133(6):1826-1829.
124. Shang A., *et al*. Are the clinical effects of homoeopathy placebo effects? Comparative study of placebo-controlled trials of homoeopathy and allopathy. *Lancet*. 2005;366:726-732.
125. Vandenbroucke J. P. Homoeopathy and “the growth of truth”. *Lancet*. 2005;366:691-692.
126. Yasgur J. Yasgur’s Homeopathic Dictionary and Holistic Health Reference. Fourth Edition. Greenville:Van Hoy Publishers. 1998.
127. All information on indomethacin, naproxen, sulindac, colchicine, allopurinol, probenecid and sulfapyrazone comes from the following sources unless otherwise noted:
 

Turkoski BB, *et al*. *Drug Information Handbook for Advanced Practice Nursing*. Huston, Ohio: Lexi-Comp.

Skidmore-Roth L, *et al*. 2008 *Mosby’s Nursing Drug Reference*. St. Louis: Mosby.

McEvoy GK, *et al*. 2006 *AHFS Drug Information*. Bethesda: American Society of Health System Pharmacists.
128. <http://investor.savient.com/ReleaseDetail.cfm?ReleaseID=291911> accessed on 2/19/08 and <http://www.savientpharma.com/pipeline/puricase.asp> Accessed on 12/29/07
129. Meigs JB, Wilson PW, Nathan DM, *et al*. Prevalence and characteristics of the metabolic syndromes in the San Antonio Heart and Framingham Offspring Studies. *Diabetes*. 2003;52:2160-2167.
130. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults. *Journal of the American Medical Association*. 2002;287:356-359.
131. Perez-Ruiz F, Calabozo M, *et al*. Renal Underexcretion of Uric Acid Is Present in Patients With Apparent High Urinary Uric Acid Output. *Arthritis & Rheumatism*. 2002;47(6):610-613.
132. [http://www.ipsen.com/articles/mediacentre/pressreleases/20080505\\_\\_\\_autorisation\\_adenu-ric\\_eu\\_10.pdf](http://www.ipsen.com/articles/mediacentre/pressreleases/20080505___autorisation_adenu-ric_eu_10.pdf) accessed on 9/9/08.
133. Hak AE, Choi HK. Menopause, Postmenopausal hormone use and serum uric acid levels in US women – The Third National Health and Nutrition Examination Survey. *Arthritis Research & Therapy* (2008). doi:10.1186/ar2519.
134. Janssens HJ, *et al*. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomized equivalence trial. *Lancet*. 2008;371:1854-1860.
135. Schlesinger N. Overview of the Management of Acute Gout and the Role of Adrenocorticotropic Hormone. *Drugs*. 2008;68(4):407-415.

136. Pope RM, Tschopp J. The Role of Interleukin-1 and the Inflammasome in Gout. *Arthritis & Rheumatism*. 2007;56(10):3183–3188.
137. Perez-Ruiz F, Calabozo M, Pijoan JI, Herrero-Beites AM, Ruibal A. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. *Arthritis & Rheumatism*. 2002;47:356–60.
138. Stocker SL, *et al*. Pharmacokinetic and Pharmacodynamic Interaction between Allopurinol and Probenecid in Healthy Subjects. *Clinical Pharmacokinetics*. 2008;47(2):111–118.
139. Dunkelgrun M, *et al*. Association Between Serum Uric Acid and Perioperative and Late Cardiovascular Outcome in Patients With Suspected or Definite Coronary Artery Disease Undergoing Elective Vascular Surgery. *The American Journal of Cardiology*. doi:10.1016/j.amjcard.2008.05.019.
140. Abrams B. How gout inhibits the development of cell-mediated autoimmune disease. *Medical Hypotheses* (2008). doi:10.1016/j.mehy.2008.08.011.
141. Alimonda AL, *et al*. Hyperuricemia in acute heart failure. More than a simple spectator? *European Journal of Internal Medicine* (2008). doi:10.1016/j.ejim.2008.04.007.
142. Ioachimescu AG, *et al*. Serum Uric Acid Is an Independent Predictor of All-Cause Mortality in Patients at High Risk of Cardiovascular Disease. *Arthritis & Rheumatism*. 2008;58(2):623–630.
143. Sui X, *et al*. Uric acid and the development of metabolic syndrome in women and men. *Metabolism Clinical and Experimental*. 2008;57:845–852.
144. Dehghan A, *et al*. Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study. doi:10.1016/S0140-6736(08)61343-4.
145. MacDonald HB. Dairy nutrition: What we knew then to what we know now. *International Dairy Journal*. doi:10.1016/j.idairyj.2008.04.001.
146. Yu KH, *et al*. Dietary Factors Associated with Hyperuricemia in Adults. *Seminars in Arthritis and Rheumatism*. 2008;37(4):243–250.
147. Sui X, *et al*. Uric acid and the development of metabolic syndrome in women and men. *Metabolism Clinical and Experimental*. 2008;57:845–852.
148. Choi HK, *et al*. Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study. *BMJ*. 2008;336:309–312.
149. Choi JJ, *et al*. Sugar-Sweetened Soft Drinks, Diet Soft Drinks, and Serum Uric Acid Level: The Third National Health and Nutrition Examination Survey. *Arthritis & Rheumatism*. 2008;59(1):109–116.
150. Underwood M. Sugary drinks, fruit, and increased risk of gout: Dietary fructose could be a contributing factor. *BMJ*. 2008;336:285–286.
151. Lorenzi A, Kelly C. What's New in Rheumatology. *Medicine*. 2008;36(8):442–446.

152. Williams, PT. Effects of diet, physical activity and performance, and body weight on incident gout in ostensibly healthy, vigorously active men. *American Journal of Clinical Nutrition*. 2008;87:1480-1487.
153. Scheinfeld N. Allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis. *Journal of the American Academy of Dermatology*. 2008;59(2):352-353.
154. Kutzing MK, Firestein BL. Altered Uric Acid Levels and Disease States. *The Journal of Pharmacology and Experimental Therapeutics*. 2008;324(1):1-7.

# I N D E X

---

## #

---

24-hour urine test, **26-27**, 37, 43

## A

---

Acidic, 26, 71

ACTH (Adrenocorticotrophic Hormone or Corticotropin), **22**, 37

Advanced Gout, 2, 8, **9-10**, 45

African Americans, 51

Age, 2, 5, 17, 27, **53**, 94

Alcohol, iv, 2, 17, 51, **64-65**, 67, 77, 78, 87, 90, 94, 97, 99, 100, 101, 102, 104, 105, 106, 107, 108, 112, 115

Alcohol abuse, **65**, 107

Allergic reactions, 18, 25, 94, 95, 97, 101, 104, 108, 109, 112

Allopurinol, iii, iv, **24-25**, 26, 28, 31, 36, 38, 43, 65, 72, **109-111**, 112, 116

Amino Acids, 82

Ankle, **6**, 42

Anti-coagulants, 17, 94, 96, 100, 104

Anti-obesity drugs, 64

Antibiotics, iv, 27, 105, 112

Artificial joints, **6**

Aspirin, 17, 52, **75**, 77, 94, 96, 97, 99, 100, 101, 102, 104, 105, 106, 108, 112, 113, 114, 115

Asymptomatic Hyperuricemia, **2-3**, 11, 35, 42

Atherosclerosis, 57

Atkin's diet, 71

Atypical gout, 7

## B

---

Baking soda, 26

Beef, **72-73**, 88, 89

Beer, iv, **64-65**, 77, 87

Big Toe, iii, v, vii, **6**, 41, 42

Binge drinking, 65

Blackberries, See cherries

Bleeding problems, **17**, 18, 19, 82, 88, 94, 95, 96, 99, 100, 103, 104, 107, 109, 111, 114, 115

Blood pressure, 26, 28, 37, 52, 55, **56**, 62, 70, 81, 95, 97, 98, 100, 101, 104, 105

Blood test, **41-42**

Body mass index (BMI), **62-63**, 65

Bone marrow disease, 20, 52, 108

Bone scans, 45

Burdock Root, 81

## C

---

Caffeine, 75

Cancer, vi, 47, 52, 54, 73, 110

Cardiovascular disease/health, 54, 55, 56, 62, 75, 81

Celery and Celery Seed, 73, 83, 90  
Cherries and Cherry Juice, **81-82**,  
88  
Chemotherapy, 52, 114  
Chills, 5, 39  
Chiropractic Therapy, 83  
Cholesterol, 28, 37, 55, 64, 70  
Chronic kidney disease/failure, 22,  
**57-58**  
Clinical diagnosis, **41-42**  
Coffee, **75**  
Colchicine - autumn crocus flower  
(formal name: Colchicum  
Autumnale), iv, v, **18-21**, 23,  
**32-34**, 35, 36, 37, 79-80, **107-**  
**109**, 113  
Cold climates, 74  
Congestive heart failure, 22, 56,  
110  
Coronary heart disease, 56, 65, 73  
Cortical cataracts, 58  
Corticosteroids, 17, **21-22**, 35, 37,  
94, 101, 105  
COX (cyclooxygenase) enzymes,  
**13-14**, 15, 18  
COX-2 inhibitors, **13-14**, 15, 36  
CT Scans, 45  
Culture, **40**, 42

**D** \_\_\_\_\_

Dairy, 70, **72-73**, 76, 77  
Desensitize, 25  
Devil's Claw, 83

Diabetes, 31, 43, 54, 55, 58, 73,  
97, 100, 104, 105, 110, 113  
Diagnostic imaging, 44-45  
Diarrhea, v, 19, 20, 95, 109  
Diet, 2, 12, 51, **61-78**, 99, 102,  
106, 108, 110, 113  
Diet to Prevent Metabolic Syn-  
drome, 67, **69-70**  
Diuretics, 52, 56, 64, 73, 81, 98,  
102, 105, 112

**E** \_\_\_\_\_

Eggs, 72, 73, 77, 88  
Elbows, 6  
Elderberries, See cherries.  
Exercise, 2, **61-64**, 67, 71, 76, 78

**F** \_\_\_\_\_

Family History, 24, 46, **51**, 56  
Fasting, 55, **71**  
Fat, 67, 69, **72-73**, 76, 77  
Fever, 5, 25, 39, 46, 47, 95, 100,  
103, 107, 109  
First attack of gout, 5, 6, 24, 34, 35  
First metatarsophalangeal joint, 5,  
6, 41, 42  
Fluctuations in blood uric acid lev-  
els, 29, 30, 32, 66, 72, 73, 74  
Flying, 75  
Folic Acid, 82  
Follow-up care, iv, vii, **31-32**  
Food Pyramid For Gout, **76-77**

Fructose, 52, 67, 69, **70-71**, 77, 78, 81

## G

---

Garlic, 73, **82**, 98, 102

Gastrointestinal Problems/Bleeding, 13, 15, **17**, 18, 19, 99, 102, 103, 106, 107, 113

Genetics, 1, 3, 25, **43**, 46, 50, 51, 53, 66, 67

Glucose, 55, 69, 70, 113

Glycemic Index, 69, 77

## H

---

Hands, 6, 8, 10, 21, 74, 77, 95

Hawthorn Berries, See cherries.

Heart Attack, 17, 19, 54, **56**, **75**, 93, 95, 97, 100, 104

Heart Disease, vi, 17, **56-57**, 65, 73, 75, 93, 97, 100, 103, 104, 107, 108

Heart Surgery, 17, 93, 94, 96, 100, 104

Herbal, 27, 79, 80, 83, 97, 98, 101, 102, 105, 108, 110, 112, 115

High-dose Colchicine, See colchicine

High-Fat Dairy, See dairy

High-Fructose Corn Syrup, See Fructose

High-resolution Ultrasound, See ultrasound

Hips, 6

Homeopathic Therapies, 83-84

Hot, humid weather (Hot environments), **74**, 77

Hydroxyapatite Arthritis, 46

Hyperlipidemia, 47, 55

Hypertension, 52, 55, 56, 110

Hypertriglyceridaemia, 52

Hypothyroidism, 52, **58**

## I

---

Ice, 23, **81-82**

Immune system, 1, 4, 5, 21, 47, 52, 84

Immunosuppressant, 25

Indomethacin, v, 14, **16**, **17**, 22, 34, 36, 37, **96-100**, 104, 112

Infection (infected), iv, 4, 8, 10, 39, 40, 42, 45, 46, 53, 108

Inflammation, iv, 5, 9, 12, 13, 16, 17, 22, 23, 36, 40, 41, 47, 80, 81, 82, 83

inflammatory bowel diseases, 25

Injection, 20, 21, 22, 35, 107, 108, 117

Insulin Resistance, 54, 55, 69, 70

Intercritical Periods, 2, **7-8**

Intermediate Gout, 8

Intestines, **50**, 95, 96, 107

**J** 

---

Joint erosions, 42

**K** 

---

Kidney Stones, **26-27**, 28, 29, 43, 44, **58**, 72, 111, 114

Kidneys, 3, 10, 17, 20, 22, 25, 26, 27, 28, 29, 43, 44, 46, 50, 51, 56, **57-58**, 70, 71, 82, 89, 95, 97, 101, 104, 107, 109, 111, 114, 115, 116

Knees, v, **6**

**L** 

---

Lead poisoning, 52

Lesions, 8, 9, 111

Leukemia, 25, 47

Liver, v, 17, 20, 29, 52, 57, 68, 89, 90, 95, 97, 101, 104, 107, 109, 114, 116

Low Pressure Environments, 74

Low Purine Diet, 68-69

Low-Fat Dairy, See dairy

Lower-Dose Colchicine, See colchicine

**M** 

---

Menopause, 5, 49, **50**, 52

Metabolic processes/systems (Metabolism), 1, 24, 49, 50, 52

Metabolic syndrome, 51, **54-55**, 56, 62, 66, 67, 69, 70, 76

mono- or poly-unsaturated fats, **89**, 77

MRI scans, 45

**N** 

---

Naproxen, **14**, 15, **16**, 22, 34, 36, 37, **100-103**, 112

Narcotics, 22, 35

Non-selective NSAIDs, 13, 14

Non-Steroidal Anti-Inflammatory Medications Drugs (NSAIDs), **13-18**, 19, 21, 22, 23, 27, 33, 35, 36, 37, 78, 82, **93-107**, 108, 113, 114, 115

Normal Uric Acid Levels, **33**, 41, 42, 43, 49, 57, 63

Nuclear Medicine, 45

Nutrition, 51, 66, 67, 70

**O** 

---

Obesity, 51, **58**, 62, 64, 70, 73

Omega-3 Supplements, 70, **72**, 76, **80-81**

Organ Transplantation Patients, 25, 52

Organ Meats, 68  
 Over-the-Counter Medications, 15,  
 17, 27, 94, 96, 98, 102, 106,  
 108, 110

## P

---

Pacific Islanders, 51  
 Pain relievers, 18, 22, 35  
 Peptic ulcers, See also, Ulcers (Gas-  
 trointestinal), 17  
 Perforation (gastrointestinal), 17,  
 99, 102, 103, 107  
 Peripheral artery disease, 56  
 pH, **26**, 37, 58, 72  
 Podagra, **4**, 6, 41  
 Polarized light, 40  
 Pork, 68, 72, 88-89  
 Pregnant, 17, 50, 53, 56, 94, 97,  
 101, 104, 108, 110, 112, 114  
 Primary Gout, 50-51, 66  
 Probenecid, iii, 10, 18, **26-28**, 31,  
 36, 37, 38, 43, 72, 75, 98, 105,  
 106, **111-114**  
 Processed Foods, 73, 87  
 Prophylaxis, 12, 19, 20, 30, **32-34**,  
 35, 36-37, 80, 82, 96, 100,  
 107, 108, 113  
 Proteins, 4, 5, 18, 47, **72-73**  
 Pseudogout, 46  
 Psoriasis, 46, 51, 52  
 Pulmonary Arterial Hypertension,  
 56  
 Punch-Out Lesions, 8

## Q

---

Quality of Life, i, viii, 7, 11, 49, 78

## R

---

Rash, **25**, 95, 100, 103, 107, 109,  
 111, 114, 115  
 Red Wine, 2, 61, **64-65**, 77  
 Rest, 22-23  
 Rheumatoid (Rheumatic) arthritis,  
 1, 39, 44, **46**, 47, 117

## S

---

Saturated Fats, 67, 70, **72-73**, 77  
 Saturation Point, 4, **74**  
 Seafood, iv, 67, **68, 70**, 76  
 Secondary Gout, 35, **51-53**  
 Selective NSAIDs, 13  
 Septic arthritis, **39-40**, 41, 46  
 Serum uric acid level (sUA), 3, 24,  
 28, 29, **31**, 36, 42, 49, 54, 56,  
 63, 66, 74, 109  
 Skimmed Milk, See dairy.  
 Skin Necrosis, 8, 10  
 Sleep Associated Hypoxemia, 51  
 Soft Tissue, v, 7, 44  
 Soy, **72-73**, 90, 91  
 Spine, 6  
 Spirits, such as Vodka, Gin and  
 Whisky, **64-65**, 77

Stomach/heartburn problems, See also, Gastrointestinal Problems/  
 Bleeding, 13, 15, **17**, 18, 19,  
 78, 82, 94, 95, 96, 97, 99, 100,  
 101, 102, 103, 104, 105, 106,  
 107, 111, 112, 113, 114, 115  
 Stroke, **17**, 19, 54, 56, **58**, 62, 93,  
 95, 97, 101, 104  
 Subcortical Cysts, 42  
 Sulfonpyrazone, **26-29**, 36, 37,  
**114-115**  
 Sulindac, **14**, **16**, 36, **104-107**  
 Super-saturated solution, See satu-  
 ration point.  
 Swelling, iii, 4, 5, 8, 18, 41, 44, 95,  
 111  
 Symptoms, v, 3, **5**, 7, 16, 17, 18,  
 19, 23, 33, 35, 37, 41, 42, 46,  
 55, 59, 94, 95, 103  
 Synovial Fluid, 4, **39-41**, 44

**T** \_\_\_\_\_

Target for uric acid lowering treat-  
 ments, **31**, 35, 42, 74  
 Tea, **75**, 81  
 Temperature, 74  
 Tenderness, 5, 41  
 Thiazides (Loop Diuretics), **52**, 110  
 Thyroid, **52**, 58  
 Tobacco, 69  
 Tophus (Tophi), **7**, 8, 9, 10, 11, 24,  
 31, 32, 33, 38, 41, 42

Toxemia of pregnancy (pre-eclamp-  
 sia), 53, 56  
 Toxicity (Toxic), v, 18, 19, 27, 80,  
 106  
 Trans fats, 69, 73  
 Triglycerides, 52, 55, 64, 81

**U** \_\_\_\_\_

Ulcers (Gastrointestinal), See also,  
 Peptic Ulcers., 17, 94, 95, 96,  
 97, 99, 101, 103, 104, 107,  
 112, 114  
 Ultrasound, **44-45**, 83  
 Urate crystals, **4**, 5, 7, 8, 9, 10, 18,  
 22, 23, 26, 39, 40, 41, 42, 43,  
 46, 74, 82, 83  
 Urate Kidney Stones, See kidney  
 stones.  
 Uricase, **1-2**, 117  
 Uricosuric Drugs, **26-29**, 31, 38,  
 43, 58, 72, **111-115**  
 Urine tests, See 24-hour urine test.

**V** \_\_\_\_\_

Vascular Diseases, 47, **53-56**, 62,  
 76, 81  
 Vegetables, **68**, 69, **73**, 76, 77,  
 90-91  
 Vitamin C, 70, **71-72**, 76, 110  
 Vomiting, iv, v, 19, 20, 95, 99, 100,  
 103, 106, 107, 109, 111, 113,  
 115

**W** \_\_\_\_\_

Waist circumference, 55

Wallace Criteria, 41

Weather, **74**, 77

Western Style Diet, 51

White Blood Cells, 4, 5, 18, 40, 52

Women, 5, 7, 24, 49, 50, 51, 52,  
54, 55, 56, 62, 79, 81, 94

Wrists, 6

**X • Y • Z** \_\_\_\_\_

X-rays, iv, v, 9, **41**, **42**, **44**

Xanthine Oxidase Inhibitor Drugs,  
**24-25**, 31, **109-111**, 116

Yellowing of the Skin and Eyes, v,  
25, 95, 111, 115